Korean J Anesthesiol.  2005 Sep;49(3):293-297. 10.4097/kjae.2005.49.3.293.

The Efficacy of BIS Monitoring for the Preventing of Withdrawal Movement on the Intravenous Injection of Rocuronium

Affiliations
  • 1Department of Anesthesiology and Pain Medicine, College of Medicine, Hallym University, Chuncheon, Korea. 89hsm@medigate.net

Abstract

BACKGROUND: Arm withdrawal movements are often observed on the administration of rocuronium. This study used the BIS to predict the depth of sedation and the prevention of withdrawal movements.
METHODS
With the approval of the institutional review board and the informed consent of the subjects, sixty patients, with ASA physical stati of 1 to 2, were randomized into four groups. After the induction of anesthesia using 0.5 mg/kg of thiopental sodium, each group received 0.6 mg/kg of rocuronium when their BIS values were 85 (Group I), 75 (Group II), 65 (Group III), or 55 (Group IV). The blood pressure, heart rate, BIS value at the time of loss of eyelash reflex, incidence of withdrawal movement and grade, and the correlation between the BIS value and loss of eyelash reflex were observed.
RESULTS
No difference were observed in the incidence of withdrawal movement and grade between the four groups. The correlation coefficients of the BIS value and time of loss of eyelash reflex were both 0.33 (P<0.05).
CONCLUSIONS
It may be impossible to rely solely on the BIS value to insure patients reach a deep anesthetic state after induction of anesthesia with thiopental. The withdrawal movement on injection of rocuronium can not be prevented with BIS monitoring.

Keyword

bispectral index; eyelash reflex; rocuronium; withdrawal movement

MeSH Terms

Anesthesia
Arm
Blood Pressure
Ethics Committees, Research
Heart Rate
Humans
Incidence
Informed Consent
Injections, Intravenous*
Reflex
Thiopental
Thiopental
Full Text Links
  • KJAE
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr